PRX

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • mrmarket
    Administrator
    • Sep 2003
    • 5971

    PRX

    $$$MR. MARKET$$$ Loves PRX
    by: mr_market63 (43/M)
    Long-Term Sentiment: Strong Buy 09/18/03 03:27 pm
    Msg: 6429 of 6458

    I’m so depressed. The Red Sox once again have failed to take the AL East title. I think I’ll reach for some Serzone. Oooops..I can’t even do that because I lost all my money betting on the Red Sox. But there is a solution. I will ingest a generic version of Serzone, called Nefazodone. It’s cheap and it works great. Wow! I’m happy already.

    Today I bought Par Pharmaceutical (PRX) at 72. I will sell it in 4 to 6 weeks at 83. Here’s why I like PRX:

    Pharmaceutical Resources (PRX) is a holding company which, through its subsidiaries, develops and markets a broad line of generic drugs in the U.S.; develops and makes in small quantities complex synthetic active pharmaceutical ingredients.

    PRX’s stock is up 283% over the last 12 months yet its PE is a very modest 27. This is a great value for the pumped up drug industry. In fact, the Value of $10,000 invested five years ago in PRX would be $ 167,875. Ladies and germs, it’s still not too late to get in. Here’s why:

    How do generic drugs work? Simple…it’s like sitting next to the smart kid during the Thermodynamics final exam. Your work isn’t necessarily original, but you end up with the same grade when you get your report card. Isn’t this how everyone got through college? Fat, drunk, and stupid is no way to live your life, is it?


    Net sales in the first half of 2003 increased 22%, year to year, reflecting new product launches, and other revenues (from a profit sharing agreement with Genpharm) in the current interim only. Gross margins widened, driven by the royalty revenue of omeprazole, but R&D costs and SG&A expenses rose significantly faster than revenues
    The financial performance of PRX is simply amazing. Return on Equity was 44% in 2002. Return on Assets,over the same period, was 31%
    Even one week before the Nefazodone coup, PRX stomped all over Paxil. Pharma Resources is a respected player in the U.S. market and will capture the majority of the generic market share (around 60%) for the rest of 2003. Pharma Resources will pick up $201 million in revenue from the sale of generic Paxil the rest of this year. Paxil sales last year totaled $2.3 billion. Holy cow! I didn’t know that many Red Sox fans existed. Generic penetration of Paxil will be 12% in the third quarter and 75% in the fourth quarter.

    With all this new business, you’re looking at a jump to about $3.97/share of earnings in 2004. With the existing PE, this would propel the stock price to $107.19/share which is well past my target. Of course you don’t have to wait until 2004 to reap these rewards. Once the market realized the gravy train is here, the stock price will be bid up well before earnings materialize.


    Among the 25 drugs currently awaiting approval by the FDA, PRX believes
    that several may represent first-to-file opportunities entitling the Company, or its strategic partner, up to 180 days of marketing exclusivity or co-exclusivity. These products include testosterone 1% gel (Androgel(R))…Where exactly do you rub this anyway?

    I am HUGE!!

    $$$MR. MARKET$$$
    =============================

    I am HUGE! Bring me your finest meats and cheeses.

    - $$$MR. MARKET$$$
  • investing_fool

    #2
    I'm likin this pick

    current price is 64.07
    support is 59.32 (50dma)
    resistance is 73.25 (52 wk hi)

    reward/risk ratio is=(73.25-64.07)/(64.07-59.32)=1.93

    so almost a 2/1 reward to risk ratio at current price, also target price (72) is below anticipated resistance (73.25).

    Comment

    • jiesen
      Senior Member
      • Sep 2003
      • 5320

      #3
      Nice comeback

      glad to see this one recovering- it had me worried for a minute (only a minute though)

      Comment

      • mrmarket
        Administrator
        • Sep 2003
        • 5971

        #4
        Re: Nice comeback

        Originally posted by jiesen
        glad to see this one recovering- it had me worried for a minute (only a minute though)
        yee of little faith...where do you think those 32 consecutive profitable trades came from??

        remember the mantra....earnings earnings earnings
        =============================

        I am HUGE! Bring me your finest meats and cheeses.

        - $$$MR. MARKET$$$

        Comment

        • CHSMITHINS

          #5
          PRX down 4 today 12/29/03

          Anyone know any news on today's PRX decline?

          Seems it could be a good day to add to position or start one. It is down on higher volume, though. The move seems company specific rather than industry although the industry has dropped on IBD over the past couple of months as the latest rotation takes place.

          I think I'll add some to lower my cost basis.

          Comment

          • viktoriya_a

            #6
            Re: PRX down 4 today 12/29/03

            Originally posted by CHSMITHINS
            Anyone know any news on today's PRX decline?

            Seems it could be a good day to add to position or start one. It is down on higher volume, though. The move seems company specific rather than industry although the industry has dropped on IBD over the past couple of months as the latest rotation takes place.

            I think I'll add some to lower my cost basis.

            Mayhap you should find out why it went down on such a good day before you add to it.

            Comment

            • mrmarket
              Administrator
              • Sep 2003
              • 5971

              #7
              Good article on PRX

              Stock Screen
              Par Excellence

              By Jack Hough
              June 17, 2004
              Note: This column was originally published on SmartMoney Select, our premium, subscription-based website. To access this and other content from SmartMoney Select on a daily basis, click here to start your FREE TRIAL now!

              "THE PAST 24 HOURS have been a Ferris wheel," remarked one analyst. "Chaos reigns," cried another. On April 7, generic-drug maker Par Pharmaceutical (PRX) announced that it had received FDA approval to sell a knock-off of Schering Plough's (DGP) Rebetol-brand ribavarin pills for Hepatitis C. Novartis (NVS) also received such an approval, but the two companies looked to have secured shared exclusivity of the drug for at least six months. Industry watchers figured the new ribavarin pill at a 35% to 40% discount to Rebetol would give Par's top line a booster shot of $50 million to $65 million in 2004. The stock quickly jumped 7%.

              The next day's news, though, had investors grimacing like toddlers swallowing cod liver oil. Schering Plough had decided not only to enter the generic market for its own drug, but also to stomp on the market with a discount of 70%. Analysts called the move "irrational," but nonetheless cut their revenue projections for Par's generic version in half. Shares immediately gave back their 7% run-up, and have kept right on falling as Reuters Research's 2004 earnings consensus for Par has shriveled to $2.75 from $3.21. The stock since April 7 is down 37%. There's reason to believe, however, that the stock has gotten cheap; it turned up recently on our Three-Point Value Screen.

              Investors differ as to which measure of a company's income they prefer to use as the basis for valuation assessments. Earnings and the price/earnings ratio are probably the most popular, and academic research suggests that earnings are more closely tied to share performance than other measures. But sales, and the corresponding price/sales ratio, are favored for their lack of reliance on extensive accounting adjustments. Cash flow, meanwhile, is the choice of those who like measuring actual money changing hands, not income being accrued and expenses incurred.

              Our Three-Point Value screen uses the P/E, P/S and P/CF ratios, along with some other measures, to find companies that look cheap from a variety of views. Engine maker Cummins (CMI), the subject of our last Three-Point Value screen on May 12 ("Diesel Power"), is an example. The loss of a major customer was just one reason investors were running from its shares at the time, but our screen suggested it was underpriced. The stock is up a quick 12% since our write-up.

              See the recipe to the right for details on the criteria used in our Three-Point Value search, and fire up our stock screener anytime you'd like to run it for yourself. This time around the screen pulled up nine companies, including Par Pharmaceutical.

              Spring Valley, N.Y.-based Par has sold $767 million worth of drugs in the past year. The company markets the 29 drugs it manufactures, and 42 drugs made by others. In the past, Par has been the first to market with generic equivalents of Prozac for depression and Megace for breast cancer. Those two drugs, and two other of Par's big sellers — generics of Paxil for anxiety and Prilosec for acid reflux — are expected to see increased competition and a decrease in revenues this year. But Par has 60 products in development and another 35 awaiting FDA approval, and its April purchase of Somerset, N.J.-based Kali Laboratories for $135 million gives it 25 more drugs in development and 14 more awaiting approval. In total, Par now expects to launch 36 products in 2004 and 2005.

              First-quarter results for the company, reported April 29, showed sales growing 99% to $211.8 million. Earnings excluding a $1.7 million gain from the sale of a facility rose 27% to $28.5 million. Per-share earnings of 80 cents met analysts' recently reduced expectations. Jeffrey Long-McGie, an analyst with stock research firm Think Equity, called the results "gut-wrenching" in an April 30 note, and figured that only 32 cents of earnings came from Par's "base business," that is, its business excluding acquisitions. But Long-McGie noted that the results were expected and called the stock "dramatically undervalued."

              Long-McGie says shares should be worth 17 times his 2005 estimate of $3.37, or about $58, within a year, and points out that there's "tremendous upside potential" to his estimate if anticipated generic competition for Paxil is delayed, or if Par launches its generic equivalent of Ultracet acid-reflux medicine, expected in the first quarter of 2005, early. (Long-McGie doesn't own shares of Par Pharmaceutical; Think Equity doesn't have an investment-banking relationship with the company.)

              A look at Reuters Research's eight-analyst consensus earnings data does nothing to contradict Long's view. Par shares trade at about $38, or 14 times 2004 earnings, compared with an average P/E of 22 for generic-drug makers. And Par is projected to increase earnings by 19% annually over the next five years, compared with 16% for the group. That gives the stock a price/earnings-growth, or PEG, ratio of 0.73, less than half of peers' 1.57 and the S&P 500's 1.60. A PEG that low suggests that the prognosis for Par's ailing shares may be promising after all.
              =============================

              I am HUGE! Bring me your finest meats and cheeses.

              - $$$MR. MARKET$$$

              Comment

              • Karel
                Administrator
                • Sep 2003
                • 2199

                #8
                Nice action! Up 17% right now for this day!

                Shall I say it? Hmm, yes, I shall:

                $$$Mr. Market$$$ is HUGE !!!

                Regards,

                Karel
                My Investopedia portfolio
                (You need to have a (free) Investopedia or Facebook login, sorry!)

                Comment

                • jiesen
                  Senior Member
                  • Sep 2003
                  • 5320

                  #9
                  Earnings tomorrow for PRX

                  PRX is announcing its quarterly earnings tomorrow, expected to be around $0.40/shr. Anyone have a guess what the real #'s going to be? I say $0.43.

                  Comment

                  • jiesen
                    Senior Member
                    • Sep 2003
                    • 5320

                    #10
                    At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.


                    Hmmm, .12 vs .40 - not good.

                    I guess they forgot to mention that .40 estimate didn't factor in the Kali acquisition, and that before that charge, they made .44... oh well. Let's just wait and see if the acquisition pays off.


                    Associated Press
                    Par Pharmaceutical 4Q Profit Plunges
                    Thursday February 24, 10:30 am ET
                    Par Pharmaceutical Fourth-Quarter Profit Plummets 89 Percent on Disappointing Sales

                    SPRING VALLEY, N.Y. (AP) -- Par Pharmaceutical Cos. reported Thursday that its fourth-quarter profit fell 89 percent, well below Wall Street expectations, as disappointing sales and increased research and development spending cut into earnings.

                    The drug maker said its quarterly income declined to $4.3 million, or 12 cents per share, down from $38.2 million, or $1.08 per share, a year ago. Revenue fell 49 percent to $114.2 million from $222.8 million last year.

                    Analysts surveyed by Thomson First Call expected earnings per share of 40 cents on revenue of $141.6 million.

                    "Certain expected new product introductions, like clonidine TDS, were delayed and the ribavirin launch proved disappointing," said Scott Tarriff, president and chief executive, in a statement. "All of these factors, along with a doubling of our investment in R&D, contributed to financial results that did not meet our expectations for the year."

                    Clonidine is a treatment for hypertension and ribavirin is a treatment for pneumonia.

                    For the full year, the company posted net income of $29.2 million, or 84 cents per share, down from $122.5 million, or $3.54 per share, last year. Excluding a research and development charge from the purchase of Kali Laboratories and a gain from the sale of a company facility, Par earned $2.26 per share.

                    Revenue rose 4 percent to $690 million from $661.7 million as the cost of goods sold rose 17 percent to $444 million. Analysts forecast earnings of $2.39 per share on revenue of $717.2 million.

                    Par Pharmaceutical shares fell 98 cents, or 2.5 percent, to $37.89 in morning trading on the New York Stock Exchange.

                    Comment

                    • spikefader
                      Senior Member
                      • Apr 2004
                      • 7175

                      #11
                      Some chart thoughts:
                      Attached Files

                      Comment

                      • jiesen
                        Senior Member
                        • Sep 2003
                        • 5320

                        #12
                        good news for PRX

                        At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

                        NovaDel Pharma Receives Approvable Letter from the FDA for NitroMist -- nitroglycerin lingual aerosol--
                        Thursday June 2, 8:30 am ET

                        FLEMINGTON, N.J.--(BUSINESS WIRE)--June 2, 2005--NovaDel Pharma Inc. (AMEX:NVD - News):
                        • No clinical issues identified
                        • Completion of process validation needed to gain approval
                        • Plans in place for Par to launch upon approval
                        NovaDel Pharma Inc. (AMEX:NVD - News) received an approvable letter from the U.S. Food and Drug Administration regarding its New Drug Application (NDA) for NitroMist(TM) (nitroglycerin lingual aerosol), indicated for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.

                        The company believes that the Food and Drug Administration will give final approval once the company completes its previously agreed-to manufacturing process validation commitments. The FDA is not requiring any additional clinical studies for approval.

                        "We are extremely pleased with this approvable letter which validates our lingual spray technology and our ability to successfully bring a product through the development and regulatory processes. Furthermore, it confirms the appropriateness of the 505(b)(2) NDA regulatory path for our lingual spray products which can reduce the time to approval," said Gary Shangold M.D., President and CEO of NovaDel. "We are already moving towards completion of the process-validation work required for approval and believe a complete response can be submitted to FDA in an expeditious manner."

                        NovaDel has partnered with Par Pharmaceutical Companies, Inc. (NYSE:PRX - News) who has exclusive rights to market, sell and distribute NitroMist(TM) in the US and Canada. NovaDel receives milestone payments and royalties on sales of the product. Manufacturing of the product will occur at the Manati, Puerto Rico facility of Inyx, Inc. (OTCBB:IYXI - News).

                        NitroMist(TM) is a pending trademark of Par Pharmaceutical Companies, Inc.

                        About NovaDel Pharma, Inc.

                        NovaDel Pharma, Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The company's proprietary lingual spray technology delivery system offers the patient the potential for (i) fast onset of action; (ii) improved drug safety by reducing the required drug dosage and reducing side effects; (iii) improved patient convenience and compliance; and (iv) enhanced dosage reliability. The company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies. To find out more about NovaDel Pharma Inc. (AMX:NVD), visit our website at www.novadel.com.

                        Comment

                        • jiesen
                          Senior Member
                          • Sep 2003
                          • 5320

                          #13
                          $25B deal for PRX

                          looks like PRX inked a huge deal last month with an Indian chemical co.
                          check it out:

                          http://www.orchidpharma.com/media_ro...fresh_deal.htm.

                          Orchid Chemicals and Pharmaceuticals Ltd today signed a fresh marketing pact with US-based Par Pharma for four non-antibiotic products for distribution in the US generics market. These four products fall under the central nervous system and anti-emetic segments, Orchid informed Bombay Stock Exchange.

                          The company has also signed a deal with Phoenix for a unique veterinary cephalosporin product covering the US, Canada and Mexico markets, it added.

                          The agreements come in the wake of two other major deals with Alpharma and Stada announced by the company recently in the non-antibiotics space.

                          These recent agreements covered several blockbuster products currently under patent and involve a development funding revenue stream of $25 million in the aggregate to the company payable in milestone linked installments between 2005 and 2007, it said.

                          The company will also receive profit share as the product get commercialised.

                          These products account for a current retail market size of $25 billion, in US and select European countries, it added.

                          The first milestone payments have already been received upon execution of the agreements, it said.

                          OCPL had earlier entered into similar agreements with Apotex and Par for distribution of its sterile and oral antibiotic formulation range of products which are set to be launched in the US from this fiscal progressively upon regulatory approvals and patent expiries.

                          Comment

                          • mrmarket
                            Administrator
                            • Sep 2003
                            • 5971

                            #14
                            Plagiarism is alive and well!


                            Yahoo! My Yahoo! Mail
                            Welcome, ebarsamian2003
                            [Sign Out, My Account]
                            Finance Home - Help



                            Welcome, ebarsamian2003 [Sign Out] My Yahoo! View - Customize
                            Financial News
                            Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup







                            AP
                            Par Gets Tentative FDA OK for Zofran
                            Friday June 17, 4:08 pm ET
                            Par Pharmaceutical Receives Tentative Approval From FDA for Generic Version of Zofran


                            SPRING VALLEY, N.Y. (AP) -- Par Pharmaceutical Cos. said Friday that the Food and Drug Administration granted the drug maker tentative approval for generic versions of GlaxoSmithKline PLC's nausea treatment Zofran ODT.
                            ADVERTISEMENT


                            The tentative approval concerns 4 milligram and 8 milligram tablets of the drug used to treat the nausea and vomiting associated with cancer chemotherapy and certain radiotherapies. Tentative approvals are granted by the FDA to generic drug makers when an application is approvable but patent and exclusivity issues are still outstanding. A tentative approval doesn't allow the applicant to market the generic product and postpones the final approval until all patent and exclusivity issues have expired.

                            Par unit Kali Laboratories Inc. filed the application in September 2002, and GlaxoSmithKline sued Kali for patent infringement. Kali denies that its product infringes GlaxoSmithKline's patents. Annual U.S. sales of Zofran ODT total about $225 million.

                            The company believes that Kali was the first to file an application for generic Zofran, which would entitle the company to 180 days of generic marketing exclusivity should it gain final approval.

                            Kali is partnered with Pliva Inc., which holds the exclusive U.S. rights to market the generic product. Under the agreement, Kali manufactures the product and the two firms split resulting profits from sales.

                            Par Pharmaceutical shares fell 17 cents to close at $31.40 on the New York Stock Exchange.
                            =============================

                            I am HUGE! Bring me your finest meats and cheeses.

                            - $$$MR. MARKET$$$

                            Comment

                            • jiesen
                              Senior Member
                              • Sep 2003
                              • 5320

                              #15
                              Originally posted by mrmarket
                              Plagiarism is alive and well!

                              Par Pharmaceutical Receives Tentative Approval From FDA for Generic Version of Zofran

                              SPRING VALLEY, N.Y. (AP) -- Par Pharmaceutical Cos. said Friday that the Food and Drug Administration granted the drug maker tentative approval for generic versions of GlaxoSmithKline PLC's nausea treatment Zofran ODT.
                              ADVERTISEMENT
                              I'm sure that's going to make some execs at GlaxoSmithKline nauseous!

                              Comment

                              Working...
                              X